亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

医学 德诺苏马布 唑来膦酸 前列腺癌 临床终点 内科学 肿瘤科 安慰剂 泌尿科 癌症 随机对照试验 骨质疏松症 病理 替代医学
作者
Karim Fizazi,Michael A. Carducci,Matthew R. Smith,Ronaldo Damião,Janet E. Brown,Lawrence I. Karsh,Piotr Milecki,Neal D. Shore,Michael Rader,Huei Wang,Qi Jiang,Sylvia Tadros,Roger Dansey,Carsten Goessl
出处
期刊:The Lancet [Elsevier BV]
卷期号:377 (9768): 813-822 被引量:1889
标识
DOI:10.1016/s0140-6736(10)62344-6
摘要

Bone metastases are a major burden in men with advanced prostate cancer. We compared denosumab, a human monoclonal antibody against RANKL, with zoledronic acid for prevention of skeletal-related events in men with bone metastases from castration-resistant prostate cancer.In this phase 3 study, men with castration-resistant prostate cancer and no previous exposure to intravenous bisphosphonate were enrolled from 342 centres in 39 countries. An interactive voice response system was used to assign patients (1:1 ratio), according to a computer-generated randomisation sequence, to receive 120 mg subcutaneous denosumab plus intravenous placebo, or 4 mg intravenous zoledronic acid plus subcutaneous placebo, every 4 weeks until the primary analysis cutoff date. Randomisation was stratified by previous skeletal-related event, prostate-specific antigen concentration, and chemotherapy for prostate cancer within 6 weeks before randomisation. Supplemental calcium and vitamin D were strongly recommended. Patients, study staff, and investigators were masked to treatment assignment. The primary endpoint was time to first on-study skeletal-related event (pathological fracture, radiation therapy, surgery to bone, or spinal cord compression), and was assessed for non-inferiority. The same outcome was further assessed for superiority as a secondary endpoint. Efficacy analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00321620, and has been completed.1904 patients were randomised, of whom 950 assigned to denosumab and 951 assigned to receive zoledronic acid were eligible for the efficacy analysis. Median duration on study at primary analysis cutoff date was 12·2 months (IQR 5·9-18·5) for patients on denosumab and 11·2 months (IQR 5·6-17·4) for those on zoledronic acid. Median time to first on-study skeletal-related event was 20·7 months (95% CI 18·8-24·9) with denosumab compared with 17·1 months (15·0-19·4) with zoledronic acid (hazard ratio 0·82, 95% CI 0·71-0·95; p = 0·0002 for non-inferiority; p = 0·008 for superiority). Adverse events were recorded in 916 patients (97%) on denosumab and 918 patients (97%) on zoledronic acid, and serious adverse events were recorded in 594 patients (63%) on denosumab and 568 patients (60%) on zoledronic acid. More events of hypocalcaemia occurred in the denosumab group (121 [13%]) than in the zoledronic acid group (55 [6%]; p<0·0001). Osteonecrosis of the jaw occurred infrequently (22 [2%] vs 12 [1%]; p = 0·09).Denosumab was better than zoledronic acid for prevention of skeletal-related events, and potentially represents a novel treatment option in men with bone metastases from castration-resistant prostate cancer.Amgen.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
mwang完成签到,获得积分10
6秒前
7秒前
李健的小迷弟应助Wakakak采纳,获得10
11秒前
lf发布了新的文献求助10
11秒前
Eunice完成签到,获得积分10
12秒前
17秒前
威武的雨筠完成签到 ,获得积分10
23秒前
研友_VZG7GZ应助哈哈哈哈采纳,获得10
26秒前
momochichu发布了新的文献求助10
27秒前
29秒前
29秒前
33秒前
Wakakak发布了新的文献求助10
34秒前
高贵逍遥完成签到 ,获得积分10
34秒前
wyz完成签到 ,获得积分10
35秒前
37秒前
冰激凌完成签到,获得积分10
38秒前
38秒前
Yu发布了新的文献求助10
40秒前
小乘号子发布了新的文献求助30
40秒前
。。完成签到,获得积分10
41秒前
量子星尘发布了新的文献求助10
43秒前
哈哈哈哈发布了新的文献求助10
44秒前
故意的山河完成签到,获得积分10
46秒前
Linda发布了新的文献求助10
48秒前
struggling2026完成签到 ,获得积分10
53秒前
科研通AI5应助Wakakak采纳,获得10
54秒前
喂喂发布了新的文献求助20
56秒前
lena完成签到 ,获得积分10
1分钟前
情怀应助小乘号子采纳,获得10
1分钟前
1分钟前
深情安青应助深情访文采纳,获得10
1分钟前
星辰大海应助科研通管家采纳,获得10
1分钟前
wanci应助科研通管家采纳,获得10
1分钟前
共享精神应助科研通管家采纳,获得10
1分钟前
大模型应助科研通管家采纳,获得30
1分钟前
1分钟前
半城微凉应助科研通管家采纳,获得10
1分钟前
万能图书馆应助Linda采纳,获得10
1分钟前
咸鱼lmye完成签到 ,获得积分20
1分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976600
求助须知:如何正确求助?哪些是违规求助? 3520700
关于积分的说明 11204482
捐赠科研通 3257320
什么是DOI,文献DOI怎么找? 1798683
邀请新用户注册赠送积分活动 877881
科研通“疑难数据库(出版商)”最低求助积分说明 806613